Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019
Ji-Won Kim, Sang Gyu Kwak, Hwajeong Lee, Seong-Kyu Kim, Jung-Yoon Choe, Sung-Hoon Park
Korean J Intern Med. 2022;37(3):673-680. Published online 2021 Mar 12 DOI: https://doi.org/10.3904/kjim.2020.633
Citations to this article as recorded by 
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis
Rouhin Sen, Maria Riofrio, Jasvinder A. Singh
Expert Opinion on Drug Safety.2024; 23(6): 687. CrossRef
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
Féline P B Kroon, Aurélie Najm, Alessia Alunno, Jan W Schoones, Robert B M Landewé, Pedro M Machado, Victoria Navarro-Compán
Annals of the Rheumatic Diseases.2022; 81(3): 422. CrossRef
COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis
Isabela Landsteiner de Sampaio Amêndola, Jonathan Aires Pinheiro, Pedro Póvoa, Vicente Cés de Souza Dantas, Rodrigo Bernardo Serafim
Journal of Clinical Medicine.2022; 11(22): 6865. CrossRef